BofA raised the firm’s price target on Concentra (CON) to $31 from $28 and keeps a Buy rating on the shares after having hosted Concentra’s team at the BofA Healthcare Conference. The “tone was bullish coming out of a strong Q1 beat and guidance raise,” says the analyst, who applies a higher multiple given increased confidence in execution.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CON:
- Concentra Earnings Call Highlights Growth, Rising Confidence
- Concentra price target raised to $32 from $29 at Deutsche Bank
- Concentra Posts Strong Q1 Results and Raises Guidance
- Concentra reports Q1 adjusted EPS 40c, consensus 34c
- Concentra raises FY26 revenue view to $2.275B-$2.375B, consensus $2.31B